292 related articles for article (PubMed ID: 30501950)
41. One-month DAPT with ticagrelor and aspirin for patients undergoing coronary artery bypass grafting: rationale and design of the randomised, multicentre, double-blind, placebo-controlled ODIN trial.
Sandner S; Gaudino M; Redfors B; Angiolillo DJ; Ben-Yehuda O; Bhatt DL; Fremes SE; Lamy A; Marano R; Mehran R; Pocock S; Rao SV; Spertus JA; Weinsaft JW; Wells G; Ruel M
EuroIntervention; 2024 Mar; 20(5):e322-e328. PubMed ID: 38436365
[TBL] [Abstract][Full Text] [Related]
42. Adenosine diphosphate-induced single-platelet count aggregation and bleeding in clopidogrel-treated patients undergoing coronary artery bypass grafting.
Dalén M; van der Linden J; Holm M; Lindvall G; Ivert T
J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):230-4. PubMed ID: 24447500
[TBL] [Abstract][Full Text] [Related]
43. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
[TBL] [Abstract][Full Text] [Related]
44. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study.
Mannacio VA; Di Tommaso L; Antignan A; De Amicis V; Vosa C
Heart; 2012 Dec; 98(23):1710-5. PubMed ID: 22942294
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
46. Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study).
Liu GZ; Zhang S; Sun DH; Shi J; Bo WL; Wang WN; Zhang CY; Wang ZH; Feng W; He MJ; Liu YY; Li S; Zheng LQ; Li Y
Eur J Clin Pharmacol; 2019 Aug; 75(8):1059-1068. PubMed ID: 31081522
[TBL] [Abstract][Full Text] [Related]
47. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
[TBL] [Abstract][Full Text] [Related]
48. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Storey RF; Bliden KP; Patil SB; Karunakaran A; Ecob R; Butler K; Teng R; Wei C; Tantry US; Gurbel PA;
J Am Coll Cardiol; 2010 Jul; 56(3):185-93. PubMed ID: 20620737
[TBL] [Abstract][Full Text] [Related]
49. Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment.
Tomšič A; Schotborgh MA; Manshanden JS; Li WW; de Mol BA
Eur J Cardiothorac Surg; 2016 Nov; 50(5):849-856. PubMed ID: 27174551
[TBL] [Abstract][Full Text] [Related]
50. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
[TBL] [Abstract][Full Text] [Related]
51. Dual platelet antiaggregation therapy after myocardial revascularization surgery.
Feitosa MPM; Soffiatti CD; Linhares Filho JPP; Batista DV; Lobo Filho HG; Lima EG; Serrano Júnior CV
Rev Assoc Med Bras (1992); 2019 Mar; 65(3):316-318. PubMed ID: 30994825
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices.
Park K; Cho YR; Park JS; Park TH; Kim MH; Kim YD
Circ Cardiovasc Interv; 2019 Oct; 12(10):e008105. PubMed ID: 31554423
[TBL] [Abstract][Full Text] [Related]
53. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
Zhuo X; Zhuo B; Ouyang S; Niu P; Xiao M
BMC Pharmacol Toxicol; 2018 Sep; 19(1):54. PubMed ID: 30176938
[TBL] [Abstract][Full Text] [Related]
54. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Kulik A; Le May MR; Voisine P; Tardif JC; Delarochelliere R; Naidoo S; Wells GA; Mesana TG; Ruel M
Circulation; 2010 Dec; 122(25):2680-7. PubMed ID: 21135365
[TBL] [Abstract][Full Text] [Related]
55. Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Une D; Al-Atassi T; Kulik A; Voisine P; Le May M; Ruel M
Circulation; 2014 Sep; 130(11 Suppl 1):S12-8. PubMed ID: 25200049
[TBL] [Abstract][Full Text] [Related]
56. Clinical efficacy of clopidogrel and ticagrelor in patients undergoing off-pump coronary artery bypass grafting: a retrospective cohort study.
Wang Z; Ma R; Li X; Li X; Xu Q; Yao Y; Wang C; Lv Q
Int J Surg; 2024 Jun; 110(6):3450-3460. PubMed ID: 38445500
[TBL] [Abstract][Full Text] [Related]
57. Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial.
Rafiq S; Johansson PI; Zacho M; Stissing T; Kofoed K; Lilleør NB; Steinbrüchel DA
Trials; 2012 Apr; 13():48. PubMed ID: 22540524
[TBL] [Abstract][Full Text] [Related]
58. [Budget impact analysis of antiplatelet therapy with ticagrelor and clopidogrel in patients with acute coronary syndrome after coronary artery bypass surgery].
Zyryanov SK; Belousov DY; Afanasyeva EV; Dumchenko EV
Ter Arkh; 2016; 88(9):39-49. PubMed ID: 27735912
[TBL] [Abstract][Full Text] [Related]
59. Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe?
Charif F; Hamdan R; Youness G; El Zein A; Issa M; Jassar Y; Younes M; Saab M
J Cardiothorac Surg; 2019 Nov; 14(1):202. PubMed ID: 31775803
[TBL] [Abstract][Full Text] [Related]
60. Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor.
Verdoia M; Rolla R; Negro F; Tonon F; Pergolini P; Nardin M; Marcolongo M; De Luca G;
Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):292-299. PubMed ID: 31780401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
